An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
Status:
Completed
Trial end date:
2008-10-19
Target enrollment:
Participant gender:
Summary
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and
beta-agonist pharmacology in preclinical studies, both pharmacologies being of long duration.
If reproduced in man, GSK961081 has the potential to deliver a medicine that can be given
once daily. The bronchodilatation after inhalation of single doses of GSK961081 alone and in
the presence of the short acting beta agonist salbutamol and the short acting muscarinic
antagonist, ipratropium bromide will be measured in this study. Any residual
bronchodilatation post-inhalation of GSK961081 and demonstrated by addition of salbutamol or
ipratropium bromide may provide an indirect assessment of the beta-agonist and antimuscarinic
components of GSK961081